Due to the lack of adequate research on its safety in these populations, Semax is not recommended for use in pregnant and breastfeeding women. Semax (Met-Glu-His-Phe-Pro-Gly-Pro, heptapeptide) is an analog of the adrenocorticotropic hormone (ACTH) N-terminal fragment (4-10), consisting of the native ACTH (4-7) fragment and C Composed of terminal tripeptide Pro-Gly-Pro. A large number of studies have shown that Semax has significant nootropic and neuroprotective effects, can improve neurological function, reduce infarct size and permanent brain damage. Currently, Semax has been successfully used in the clinical treatment of stroke, cerebrovascular insufficiency, and optic atrophy. Neonatal administration of Semax has been shown to reduce anxiety and improve learning in adult rats. In addition, studies have shown that semax peptide at a dose of 50 μg/kg body weight can be used to treat epilepsy.